Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-1388 HIV Vaccine in CMV-seropositive Adults
NCT07801456Phase 1Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, randomised trial in human immunodeficiency virus infection (HIV) comparing VIR-1388 with Placebo (2 arms). Primary endpoints: Number of Participants with Local Reactions, Number of Participants with Systemic Reactions and 5 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
VIR-1388
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07801456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801456.